Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Single-nucleotide mutations in the Epidermal Growth Factor Receptor (EGFR) gene are linked to lung cancer development.
• EGFR tyrosine kinase inhibitors (EGFR-TKIs) are vital for treating EGFR-mutated lung cancers, but acquired resistance poses a significant clinical challenge.
• Monitoring both de novo and acquired EGFR mutations is crucial for effective lung cancer management with EGFR-TKIs.

Purpose of the Study:

• To evaluate the efficacy of oligoribonucleotide interference-PCR (ORNi-PCR) for the simultaneous detection of de novo (L858R) and acquired (T790M) EGFR mutations in lung cancer.
• To establish optimal ORNi-PCR conditions for detecting these specific mutations in both genomic DNA and complementary DNA (cDNA).

Main Methods:

• Optimization of ORNi-PCR experimental conditions for simultaneous detection of L858R and T790M mutations in EGFR.
• Application of ORNi-PCR to detect target mutations in genomic DNA and cDNA derived from lung cancer cells.
• Assessment of ORNi-PCR's sensitivity in detecting rare mutant cells within a mixed population of wild-type cells.

Main Results:

• Established optimal ORNi-PCR conditions for simultaneous detection of de novo L858R and acquired T790M EGFR mutations.
• Demonstrated successful application of ORNi-PCR for both genomic DNA and RNA-derived cDNA.
• Showcased ORNi-PCR's high sensitivity, capable of detecting mutant cells at frequencies as low as ~0.2% in a wild-type background.

Conclusions:

• ORNi-PCR is a precise and cost-effective method for simultaneously detecting multiple single-nucleotide mutations in the EGFR gene.
• This technique holds significant potential for clinical applications, particularly in the simultaneous monitoring of diverse EGFR mutations during lung cancer treatment.